Skip to content

The effect of bariatric surgery on pharmacotherapy of psychotropic drugs

The effect of bariatric surgery on pharmacotherapy of psychotropic drugs in clinical practice

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29532
Enrollment
Unknown
Registered
2018-09-13
Start date
2018-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bariatric surgery antidepressivs antipsychotics dosage

Interventions

n.v.t. Het draait om een observationeel onderzoek met invasieve metingen.

Sponsors

St Antonius hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Indication for bariatric surgery (i.e. Body Mass Index (BMI) > 40 kg/m2 or BMI> 35 kg/m2 with additional risk factors) at St Antonius hospital. Bariatric surgery includes the following procedures: laparoscopic (mini-) gastric bypass or laparoscopic sleeve gastrectomy; - Participant between 18 and 60 years old; - ASA physical classification II or III; - Participant is able and willing to sign the Informed Consent form before the screening; - Intake and follow up by the Dutch Obesity Clinic (in groups sessions); - Participant suffers from psychopathology and uses one of the following psychotropic drugs: • Amitriptyline • Nortriptyline • Clomipramine • Haloperidol • Clozapine • Imipramine • Olanzapine • Paroxetine • Risperidon • Sertraline • Venlafaxine • Zuclopenthixol • Fluvoxamine • Fluoxetine • Citalopram • Quetiapine

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Known allergy for the administered medicine; - Pregnancy or breast-feeding. This is an exclusion criterion for bariatric surgery (participants are informed by their surgeon and bariatric nurse). Women of childbearing age who use contraceptive methods are allowed to participate in the study.

Design outcomes

Primary

MeasureTime frame
Main study endpoint is the change in drug concentrations in plasma (therapeutic drug monitoring) (mg/L) of the psychotropic drug after bariatric surgery (at 1, 3, 6 and 12 months) compared to the drug concentrations in plasma (therapeutic drug monitoring) before bariatric surgery corrected by the dosage.

Secondary

MeasureTime frame
Secondary endpoint is: - the change in mental status, evaluated by the Brief Symptom Inventory (BSI)- questionnaire, after bariatric surgery (at 1, 3, 6 and 12 months), compared to before bariatric surgery

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)